2-cyano-N-(naphthalen-1-ylmethyl)acetamide | 566926-34-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-cyano-N-(naphthalen-1-ylmethyl)acetamide
• CAS: 566926-34-9
• 化学式: C₁₄H₁₂N₂O
• mdl: MFCD17472485
• 分子量: 224.262
• InChiKey: CPQWFDIMOUVQMD-UHFFFAOYSA-N

物化性质

• 沸点：
  518.8±43.0 °C(Predicted)
• 密度：
  1.188±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  52.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  7-甲氧基香豆素 、 2-cyano-N-(naphthalen-1-ylmethyl)acetamide 在 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 24.0h， 生成 5-amino-8-methoxy-3-(naphthalen-1-ylmethyl)-1H-chromeno[3,4-c]pyridine-2,4(3H,10bH)-dione
  参考文献：
  名称：

  Discovery of chromenes as inhibitors of macrophage migration inhibitory factor

  摘要：

  Macrophage migration inhibitory factor (MIF) is an essential signaling cytokine with a key role in the immune system. Binding of MIF to its molecular targets such as, among others, the cluster of differentiation 74 (CD74) receptor plays a key role in inflammatory diseases and cancer. Therefore, the identification of MIF binding compounds gained importance in drug discovery. In this study, we aim to discover novel MIF binding compounds by screening of a focused compound collection for inhibition of its tautomerase enzyme activity. Inspired by the known chromen-4-one inhibitor Orita-13, a focused collection of compounds with a chromene scaffold was screened for MIF binding. The library was synthesized using versatile cyanoacetamide chemistry to provide diversely substituted chromenes. The screening provided inhibitors with IC50's in the low micromolar range. Kinetic evaluation suggested that the inhibitors were reversible and did not bind in the binding pocket of the substrate. Thus, we discovered novel inhibitors of the MIF tautomerase activity, which may ultimately support the development of novel therapeutic agents against diseases in which MIF is involved. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2017.12.032
• 作为产物：
  描述：

  1-萘甲基胺 、 氰乙酸甲酯 生成 2-cyano-N-(naphthalen-1-ylmethyl)acetamide
  参考文献：
  名称：

  Cyanoacetamides (IV): Versatile One-Pot Route to 2-Quinoline-3-carboxamides

  摘要：

  Cyanoacetic acid derivatives are the starting materials for a plethora of multicomponent reaction (MCR) scaffolds. Herein, we describe scope of a valuable general protocol for the synthesis of arrays of 2-aminoquinoline-3-carboxamides from cyanoacetamides and 2-aminobenzaldehydes or heterocyclic derivatives via a Friedlander reaction variation. In many cases, the reactions involve a very convenient work up by simple precipitation and filtration. More than 40 new products are described. We foresee our protocol and the resulting derivatives becoming very valuable to greatly expanding the scaffold space of cyanoacetamide derivatives.

  DOI：

  10.1021/co3000133

文献信息

• Modulators of LXR
  申请人：——

  公开号：US20030181420A1

  公开（公告）日：2003-09-25

  Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of nuclear receptors, including liver X receptor (LXR) and orphan nuclear receptors. In certain embodiments, the compounds are N-substituted pyridones.

  提供了用于调节核受体活性的化合物、组合物和方法。具体来说，提供了用于调节核受体活性的杂环化合物，包括肝X受体（LXR）和孤儿核受体。在某些实施方式中，这些化合物是N-取代吡啶酮。
• Thieno[2,3-<i>d</i>]pyrimidine-2,4(1<i>H</i>,3<i>H</i>)-dione Derivative Inhibits <scp>d</scp>-Dopachrome Tautomerase Activity and Suppresses the Proliferation of Non-Small Cell Lung Cancer Cells
  作者：Zhangping Xiao、Angelina Osipyan、Shanshan Song、Deng Chen、Reinder A. Schut、Ronald van Merkerk、Petra E. van der Wouden、Robbert H. Cool、Wim J. Quax、Barbro N. Melgert、Gerrit J. Poelarends、Frank J. Dekker

  DOI：10.1021/acs.jmedchem.1c01598

  日期：2022.2.10

  The homologous cytokines macrophage migration inhibitory factor (MIF) and d-dopachrome tautomerase (d-DT or MIF2) play key roles in cancers. Molecules binding to the MIF tautomerase active site interfere with its biological activity. In contrast, the lack of potent MIF2 inhibitors hinders the exploration of MIF2 as a drug target. In this work, screening of a focused compound collection enabled the

  同源细胞因子巨噬细胞迁移抑制因子 (MIF) 和d-多巴色素互变异构酶 ( d -DT 或 MIF2) 在癌症中起关键作用。与 MIF 互变异构酶活性位点结合的分子会干扰其生物活性。相比之下，缺乏有效的 MIF2 抑制剂阻碍了将 MIF2 作为药物靶点的探索。在这项工作中，筛选集中的化合物集合能够识别 MIF2 互变异构酶抑制剂 R110。随后的优化为抑制剂5d提供了对 MIF2 互变异构酶活性的 IC 50为 1.0 μM 和对 MIF 的高选择性。5天抑制二维 (2D) 和三维 (3D) 细胞培养物中非小细胞肺癌细胞的增殖，这可以通过失活促分裂原活化蛋白激酶 (MAPK) 诱导细胞周期停滞来解释) 途径。因此，我们发现并表征了 MIF2 抑制剂 ( 5d ) 在细胞模型系统中具有改善的抗增殖活性，这表明靶向 MIF2 在癌症治疗中的潜力。
• Aminoisoxazole derivatives active as kinase inhibitors
  申请人：Cavicchioli Marcello

  公开号：US20050059657A1

  公开（公告）日：2005-03-17

  Compounds (I) which are aminoisoxazole derivatives or pharmaceutically acceptable salts thereof, together with pharmaceutical compositions comprising them are disclosed; these compounds or compositions are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders.

  本发明涉及氨基异噁唑衍生物(I)或其药学上可接受的盐，以及包含它们的药物组合物。这些化合物或组合物在治疗由蛋白激酶活性改变引起和/或相关的疾病方面具有用途，例如癌症、细胞增殖性疾病、阿尔茨海默病、病毒感染、自身免疫性疾病和神经退行性疾病。
• AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS
  申请人：Pharmacia Italia S.p.A.

  公开号：EP1435948A1

  公开（公告）日：2004-07-14
• US7998986B2
  申请人：——

  公开号：US7998986B2

  公开（公告）日：2011-08-16